Guillain-Barré Syndrome Does Not Cause Primary Myopathy
No, Guillain-Barré syndrome (GBS) is fundamentally a disease of peripheral nerves and nerve roots, not muscle tissue—it is an immune-mediated polyradiculoneuropathy, not a myopathy 1.
Understanding the Pathophysiology
GBS is definitively characterized as an inflammatory disease of the peripheral nervous system (PNS) that damages peripheral nerves and nerve roots through immune-mediated mechanisms 1. The disease process involves:
- Complement activation and macrophage infiltration targeting peripheral nerves
- Antibodies against gangliosides in nerve axolemma
- Demyelination or axonal injury to peripheral nerves
- No primary inflammatory or immune attack on muscle tissue itself
The electrophysiological subtypes (AIDP, AMAN, AMSAN) all reflect nerve pathology—demyelinating or axonal—not muscle disease 1.
The Critical Diagnostic Distinction
When evaluating a patient with suspected GBS, inflammatory myositis and drug-induced toxic myopathy are explicitly listed as differential diagnoses that must be ruled OUT 1. This guideline explicitly distinguishes GBS from true muscle diseases, emphasizing they are separate entities.
Key Differentiating Features:
- GBS: Areflexia/hyporeflexia, distal-to-proximal ascending weakness, sensory involvement, nerve conduction abnormalities
- Myopathy: Normal or preserved reflexes (until very advanced), proximal > distal weakness typically, elevated CK, myopathic EMG patterns
Secondary Muscle Changes Are Not Myopathy
While one older research study 2 documented muscle biopsy changes in early GBS (necrosis, phagocytosis, ultrastructural abnormalities), these represent secondary denervation changes from nerve injury, not primary myopathy. This is analogous to muscle atrophy seen in any denervating condition—the muscle is an innocent bystander suffering from loss of nerve supply.
The Clinical Pitfall to Avoid
Critical illness myopathy can coexist with or mimic GBS 3, particularly in ICU patients. When EMG shows both neuropathic and myopathic features in a critically ill patient with respiratory failure, this represents two separate disease processes (GBS plus critical illness myopathy from prolonged immobilization, sepsis, or corticosteroid use), not GBS "causing" myopathy.
The 2019 EAN guideline 1 makes no mention of myopathy as a complication, manifestation, or consequence of GBS across its comprehensive ten-step diagnostic and management framework. Long-term residual problems include incomplete motor recovery, neuropathic pain, and fatigue 1—but not myopathy.
In clinical practice: If you suspect both GBS and myopathy in the same patient, investigate for separate concurrent causes (infection, medications, critical illness, metabolic derangements) rather than attributing muscle disease to the GBS itself.